95 related articles for article (PubMed ID: 23544708)
1. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
3. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
Gnanadhas DP; Dash PK; Sillman B; Bade AN; Lin Z; Palandri DL; Gautam N; Alnouti Y; Gelbard HA; McMillan J; Mosley RL; Edagwa B; Gendelman HE; Gorantla S
J Clin Invest; 2017 Mar; 127(3):857-873. PubMed ID: 28134625
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages.
Aquaro S; Borrajo A; Pellegrino M; Svicher V
Virulence; 2020 Dec; 11(1):400-413. PubMed ID: 32375558
[TBL] [Abstract][Full Text] [Related]
5. The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.
Gendelman HE; McMillan J; Bade AN; Edagwa B; Kevadiya BD
Trends Microbiol; 2019 Jul; 27(7):593-606. PubMed ID: 30981593
[TBL] [Abstract][Full Text] [Related]
6. Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
Gao Y; Kraft JC; Yu D; Ho RJY
Eur J Pharm Biopharm; 2019 May; 138():75-91. PubMed ID: 29678735
[TBL] [Abstract][Full Text] [Related]
7. Creation of a long-acting nanoformulated dolutegravir.
Sillman B; Bade AN; Dash PK; Bhargavan B; Kocher T; Mathews S; Su H; Kanmogne GD; Poluektova LY; Gorantla S; McMillan J; Gautam N; Alnouti Y; Edagwa B; Gendelman HE
Nat Commun; 2018 Feb; 9(1):443. PubMed ID: 29402886
[TBL] [Abstract][Full Text] [Related]
8. Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.
Kevadiya BD; Bade AN; Woldstad C; Edagwa BJ; McMillan JM; Sajja BR; Boska MD; Gendelman HE
Acta Biomater; 2017 Feb; 49():507-520. PubMed ID: 27916740
[TBL] [Abstract][Full Text] [Related]
9. Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
Martinez-Skinner AL; Araínga MA; Puligujja P; Palandri DL; Baldridge HM; Edagwa BJ; McMillan JM; Mosley RL; Gendelman HE
PLoS One; 2015; 10(12):e0145966. PubMed ID: 26716700
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
Nelson AG; Zhang X; Ganapathi U; Szekely Z; Flexner CW; Owen A; Sinko PJ
J Control Release; 2015 Dec; 219():669-680. PubMed ID: 26315816
[TBL] [Abstract][Full Text] [Related]
11. Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.
Gendelman HE; Anantharam V; Bronich T; Ghaisas S; Jin H; Kanthasamy AG; Liu X; McMillan J; Mosley RL; Narasimhan B; Mallapragada SK
Nanomedicine; 2015 Apr; 11(3):751-67. PubMed ID: 25645958
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.
Gautam N; Puligujja P; Balkundi S; Thakare R; Liu XM; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2014 Dec; 58(12):7510-9. PubMed ID: 25288084
[TBL] [Abstract][Full Text] [Related]
14. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.
Edagwa BJ; Zhou T; McMillan JM; Liu XM; Gendelman HE
Curr Med Chem; 2014; 21(36):4186-98. PubMed ID: 25174930
[TBL] [Abstract][Full Text] [Related]
15. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
[TBL] [Abstract][Full Text] [Related]
16. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
17. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
18. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
[TBL] [Abstract][Full Text] [Related]
19. Peptidomimetic inhibitors of HIV protease.
Randolph JT; DeGoey DA
Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
